Royalty Pharma PLC reports results for the quarter ended September 30 - Earnings Summary

• Royalty Pharma PLC reported quarterly adjusted earnings of $1.21​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $1.17. The mean expectation of seven analysts for the quarter was for earnings of $1.18 per share. Wall Street expected results to range from $1.15 to $1.22 per share.

• Revenue fell 15.2% to $690.10 million from a year ago; analysts expected $796.53 million.

• Royalty Pharma PLC's reported EPS for the quarter was 26 cents​.

• The company reported quarterly net income of $144.68 million.

• Royalty Pharma PLC shares had risen by 13.8% this quarter and gained 71.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.6% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Royalty Pharma PLC is $66.00, about 0.6% below its last closing price of $66.40

This summary was machine generated from LSEG data November 4 at 03:07 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)